Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial

Pediatric Pulmonology

Volumn 47, Issue 6, 2012, Pages 551-557

  Robinson, P ^a   Schechter, Michael S ^b   Sly, Peter D ^c   Winfield, Kaye ^d   Smith, Julie ^e   Brennan, Siobhain ^d   Shinkai, Masaharu ^f   Henke, Markus O ^g   Rubin, Bruce K ^h  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clarithromycin; cystic fibrosis; cytokines; pulmonary function; quality of life

Indexed keywords

AUTACOID; AZITHROMYCIN; CLARITHROMYCIN; INTERLEUKIN 8; MACROLIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL FLORA; BODY HEIGHT; BODY WEIGHT; BREATH CONDENSATE; CHILD; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COUGH TRANSPORTABILITY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; IMMUNOMODULATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MUCOCILIARY TRANSPORTABILITY; NASAL POTENTIAL DIFFERENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT PARAMETERS; SIDE EFFECT; SINUSITIS; SPUTUM ANALYSIS; SPUTUM TRANSPORTABILITY; SURFACE PROPERTY; WEIGHT REDUCTION; WETTABILITY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; CROSS-OVER STUDIES; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOMODULATION; MALE; PROTEIN SYNTHESIS INHIBITORS; QUALITY OF LIFE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84862796502     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21613     Document Type: Article

References (24)

1. Jaffe A, Francis J, Rosenthal M, Bush A,. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420. (Pubitemid 28064175)
2. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III., Azithromycin patients in with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756. (Pubitemid 37430625)
3. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Roe LH, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeuriginosa: a randomized controlled trial. JAMA 2010; 330: 1707-1715.
4. McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S,. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Resp J 2007; 30: 487-495. (Pubitemid 351182072)
5. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP,. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61: 895-902. (Pubitemid 44570311)
6. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med 2009; 180: 802-808.
7. Oishi K, Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, Matsumoto K,. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-4152. (Pubitemid 24301936)
8. Khan AA, Slifer TR, Araujo FG, Remington JS,. Effect of Clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11: 121-132. (Pubitemid 29114971)
9. Takizawa H, Desaki M, Ohtoshi T, Kawasaki S, Kohyama T, Sato M, Tanaka M, Kasama T, Kobayashi K, Nakajima J, et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266-271. (Pubitemid 27293200)
10. Shinkai M, Henke MO, Rubin BK,. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharm Ther 2008; 117: 393-405.
11. Kanoh S, Rubin BK,. Macrolides as immunomodulatory medications. Mechanisms of action and clinical applications. Clin Microbiol Rev 2010; 23: 590-615.
12. Oda H, Kadota J-I, Kohno S, Hara K,. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 1116-1123. (Pubitemid 24309549)
13. Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S,. Erythromycin does not directly affect neutrophil functions. Chest 1994; 105: 520-523. (Pubitemid 24066728)
14. Tamaoki J, Kadota J, Takizawa H,. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117: 5S-11S.
15. Pukhalsky A, Shmarina G, Kapranov N, Kokarovtseva S, Pukhalskaya D, Kashirskaja N,. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediat Inflamm 2004; 13: 111-117. (Pubitemid 38698140)
16. Ordoñez CL, Stulbarg M, Grundland H, Liu JT, Boushey HA,. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Ped Pulmon 2001; 32: 29-37.
17. American Thoracic Society Committee on Diagnostic Standards for Non-Tuberculous Respiratory Diseases. Standardization of spirometry 1994 update. Am J Resp Crit Care Med 1995; 152: 1107-1136.
18. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B,. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 127: 725-734. (Pubitemid 13101554)
19. Quittner AL, Buu A, Watrous M, Davis MA,. The Cystic Fibrosis Questionnaire (CFQ): user's manual. Washington, DC: Cystic Fibrosis Foundation; 2000.
20. Barker PM, Gillie DJ, Schechter MS, Rubin BK,. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am J Resp Crit Care Med 2005; 171: 868-871. (Pubitemid 40562717)
21. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, Kohno S,. Long term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97: 844-850. (Pubitemid 36763898)
22. Sandrini A, Balter MS, Chapman KR,. Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J 2003; 10: 449-451. (Pubitemid 38195710)
23. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010; 303: 1707-1715.
24. udoh S, Azuma A, Yamamoto M, Izumi T, Ando M,. Improvement in survival in patients with diffuse panbronchiolitis treated with erythromycin. Am J Resp Crit Care Med 1998; 157: 1829-1832.